Abstract
Vemurafenib has significantly improved overall survival and disease- free survival of patients with BRAF V600 mutation metastatic melanoma. However, this small-molecule inhibitor of BRAF is associated with skin toxicity.
The most frequent adverse skin events include UVA photosensitivity, keratoacanthomas, skin papillomas and hand-foot skin reaction. A 61-year-old woman, skin phototype II, who had presented 4 years previously with a superficial spreading melanoma with a Breslow thickness of 1.6 mm on her back, was found to have extensive metastatic disease of the liver.
Treatment was initiated with vemurafenib (960 mg bid). Within 2 weeks she started to complain about arthralgia in the joints of the legs.
Due to chronic gastritis we tried to avoid non-steroidal anti-inflammatory drugs (NSAID) and paracetamol was recommended. Her chronic medication contained aluminium hydroxide intake.